В эпидемиологической программе МАГНИТ изучалась частота встречаемости микроальбуминурии (МАУ) у пациентов с артериальной гипертензией (АГ). Методы. Обследовано 5607 пациентов с АГ, из которых пригодными для анализа оказались 5311 (44% мужчин и 56% женщин) в возрасте 56,5±12,3 года и артериальным давлением (АД) 151,2±18,3/90,6±10,5 мм рт. ст. Индекс массы тела (ИМТ) составил 30,4±4,9 кг/м2, окружность талии (ОТ) 99,0±14,3 см. МАУ определялась с помощью тест-полосок. В зависимости от результатов обследования пациенты были разделены на группы: отсутствие МАУ, с МАУ (30–300 мг) и с протеинурией (альбуминурия >300 мг). Результаты. Распространенность МАУ и протеинурии у пациентов с АГ составила 59,9 и 6,8% соответственно. Антигипертензивную терапию получали 83,7% больных. Целевого уровня АД достигли 13,7%. Наличие МАУ коррелировало с сахарным диабетом типа 2 (r=0,20; p<0,001), величиной систолического и диастолического АД (r=0,20; p<0,001), ИМТ (r=0,29; p<0,001), ОТ (r=0,32; p<0,001) и абдоминальным ожирением (r=0,26; p<0,001). Заключение. МАУ часто встречается у пациентов с АГ, и ее определение рекомендовано всем больным с повышенным АД, особенно при наличии избыточной массы тела и ожирения.
The aim of MAGNIT epidemiology program was investigating the prevalence of microalbuminuria (MAU) in patients with arterial hypertension (AH). Methods. We evaluated 5311 outpatients with AH, 44% of men, age 56,5±12,3 and blood pressure (BP) 151,2±18,3/90,6±10,5 mm Hg. Body mass index (BMI) was 30,4±4,9 kg/m2, waist circumference 99,0±14,3 cm. MAU was estimated using strip-test. Patients were categorized as MAU is absent, with MAU (30–300 mg) and proteinuria (albuminuria >300 mg). Results. The prevalence of MAU and proteinuria in patients with AH was 59,9 and 6,8% respectively. Most of the patients (83,7%) received antihypertensive therapy. Target BP levels were achieved in 13,7% of patients. MAU was significantly associated with diabetes mellitus (r=0,20; p<0,001), systolic and diastolic BP (r=0,20; p<0,001), BMI (r=0,29; p<0,001), waist circumference (r=0,32; p<0,001) and abdominal obesity (r=0,26; p<0,001). Conclusions. MAU is highly prevalent in patients with AH and MAU assessment is recommended to all patients with high BP, especially overweight and obese.
1. Epstein M, Parving HH, Ruilope LM. Surrogat endpoints and renal pritection: focus on microalbuminuria. Blood Pressure 1997; 6: 52–7.
2. Ruilope LM, Guerrero L, Casal M et al. Tolerance to nitrendipine in patients with arterial hypertension accompanying chronic renal failure. J Cardiovasc Pharmacol 1991; 18: 71–3.
3. Ruilope LM, Rodicio JL. Microalbuminuria in clinical practice. Kidney: a Current Survey of World Literature 1995; 4: 211–6.
4. Ruilope LM, Alcazar JM, Rodicio JL. Renal conseguences of arterial hypertension. J Hypertens 1992; 10: 85–90.
5. Schlessinger SD, Tankersey MR, Crtis JJ. Clinical documentation or end-stage renal disease due to hypertension. Am J Kidney Dis 1994; 23: 655–60.
6. Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria with diabetes mellitus. Ann Intern Med 1990; 122: 707–8.
7. Redon J, Baldo E, Lurbe E et al. Microalbuminuria, left ventricular mass and ambulatory blood pressure in essential hypertension. Kidney Int 1996; 55: 81–4.
8. Potremoli R, Nicolella C, Viazzi F et al. Microalbuminuria in an early marker of target organ damage in essential hypertension. Am J Hypertens 1998; 11: 430–8.
9. Jensen JS, Borch JK, Jensen et al. Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subject. Clin Sci Colch 1995; 88: 629–33.
10. Diercks GF, van Boven AJ, Hillege HL et al. Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The PREVEND (Prevention of Renal and Vascular Endstage Disease) study. Eur Heart J 2000; 21: 1922–7.
11. Титов В.Н., Тарасов А.В. Микроальбуминурия: патофизиология, диагностическое значение и методы исследования. Тер. арх. 1988; с. 134–40.
12. Mogensen CE, Keane WF, Bennett IH et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080–4.
13. Parving HH Microalbuminuria in essential hypertension and diabetes mellitus. J Hypertens 1996; 14: 89–94.
14. Krieg M, GunBer KI, Becrer H. J Clin Chem clin Biochem 1986; 24: 863–9.
15. Garg AX, Kiberd BA, Clark WF et al. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int 2002; 61: 2165–75.
16. Mimran A, Ribstein J, Du Cailar G. Is microalbuminuria a marker of intrarenal vascular dysfunction in essential hypertension? Hypertension 1994; 223: 1018–21.
17. Диагностика и лечение артериальной гипертензии. Российские рекомендации (4-й пересмотр). Системные гипертензии. 2010; 3: 3–25.
18. Gasic S, Wagner OF, Fasching P et al. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Am J Hypertens 1999; 12 (2 Pt. 1): 217–22.
19. Руководство по артериальной гипертонии под редакцией акад. Е.И.Чазова, проф. И.Е.Чазовой. М.: Медиа Медика, 2005.
20. Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719–28.
21. Douglas JG, Agodoa L. ACE inhibition is effective and renoprotective in hypertensive nephroscle-rosis: the African American Study of Kidney Disease and Hypertension (AASK) trial. Kidney Int 2003; 83 (Suppl.): 74–6.
22. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-con-verting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53.
23. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non-diabetic individuals. JAMA 2001; 286: 421–6.
24. Redon J. Introduction. Telmisartan in the treatment of hypertension--addressing the early morning risk: international experiences in different populations. Int J Clin Pract Suppl 2004; 145: 1–2.
25. Cupisti A, Rizza G, D'Alessandro C et al. Effect of telmisartan on the proteinuria and circadian blood pressure profile in chronic renal patients. Biomed Pharmacother 2003; 57 (3–4): 169–72.
26. Bakris G, Burgess E, Weir M on behalf of the AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008; 74 (3): 364–9.
27. ONTARGET Investigators, Yusuf S, Teo K, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.
28. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672–8.
29. Hollenberg NK, Parving HH, Viberti G et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25: 1921–6.
30. Kaplan NM. Clinical Hypertension. Ten edition, Lippincott Williams & Wilkins, 2010.
31. Parving H-H et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433–46.